Digene/Cytyc merger extended once again:
This article was originally published in Clinica
The expiry date of Cytyc's proposed purchase of Digene, which has already been extended a number of times, has been put back again - to June 27. Earlier this month, shares in both companies dropped after Roche Diagnostics bought a patent portfolio relating to human papillomavirus (HPV) (see Clinica No 1011, p 15). Digene has the only FDA-approved test for HPV.